The FDA requires manufacturers to assess the cardiovascular risk of all new therapies for type 2 diabetes. Semaglutide, a glucagon like peptide-1 analogue, lowers blood glucose, but does it increase cardiovascular risk? New research findings are summarized in a short video.
More findings in
N Engl J Med 2016; 375:1834-1844November 10, 2016DOI: 10.1056/NEJMoa1607141